Enfortumab vedotin
Appearance
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | gamma 1-chain |
Clinical data | |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
ChemSpider |
|
Chemical and physical data | |
Formula | C6642H10284N1742O2063S46 |
Molar mass | 149.0 kg/mol g·mol−1 |
Enfortumab vedotin[2] is a monoclonal antibody designed for the treatment of cancer expressing Nectin-4.[3]
This drug was developed by Seattle Genetics Inc.
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enfortumab Vedotin, American Medical Association.